Literature DB >> 22419733

Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity?

Olga Pivovarova1, Özlem Gögebakan, Nora Klöting, Andrea Sparwasser, Martin O Weickert, Isam Haddad, Victoria J Nikiforova, Andreas Bergmann, Michael Kruse, Anne-Cathrin Seltmann, Matthias Blüher, Andreas F H Pfeiffer, Natalia Rudovich.   

Abstract

CONTEXT: Natriuretic peptides (NP) regulate cardiovascular homeostasis and have multiple metabolic properties. Decreased levels of NP or "natriuretic handicap" are signs of insulin resistance such as central obesity. Increased expression of NP clearance receptor (NPRC) in sc adipose tissue (SAT) was observed in insulin-resistant subjects.
OBJECTIVE: We hypothesized that insulin acutely regulates NP receptor expression in adipose tissue. DESIGN AND PARTICIPANTS: NPRA, NPRB, and NPRC mRNA expression was measured in paired samples of visceral adipose tissue (VAT) and SAT from 157 subjects (108 with type 2 diabetes). The effect of insulin on NPR gene expression in SAT was studied in euglycemic-hyperinsulinemic and hyperglycemic-hyperinsulinemic clamp experiments. Additionally, the effect of insulin and glucose on NPR expression in the culture of primary human monocytes and macrophages was tested.
RESULTS: NPRA and NPRC gene expression was higher in VAT compared with SAT (P < 0.01), but only NPRC gene expression strongly correlated with fasting insulin levels (r = 0.65, P = 0.04 × 10(-3); and r = 0.54, P = 0.002, for VAT and SAT, respectively). NPRB expression was lower in VAT than in SAT in subjects with type 2 diabetes and was lower compared with nondiabetic subjects. NPRC gene expression was up-regulated in SAT during both euglycemic- and hyperglycemic-hyperinsulinemic clamps (P = 0.038 and P = 0.048, respectively), and was increased in high glucose and insulin treatment in monocytes (70.2%; P = 0.01), but not in mature macrophages.
CONCLUSION: Insulin increased expression of NPRC in SAT independently of circulating glucose concentrations. Thus, insulin might suppress circulating NP via up-regulation of NPRC expression in obesity, providing a novel link between hyperinsulinemia and obesity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22419733     DOI: 10.1210/jc.2011-2839

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

Review 1.  Nutrition and metabolic correlates of obesity and inflammation: clinical considerations.

Authors:  Amy R Johnson; Liza Makowski
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

Review 2.  A heart-adipose tissue connection in the regulation of energy metabolism.

Authors:  Sheila Collins
Journal:  Nat Rev Endocrinol       Date:  2013-12-03       Impact factor: 43.330

3.  BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.

Authors:  Umair Khalid; Lisa Miller Wruck; Pedro Miguel Quibrera; Biykem Bozkurt; Vijay Nambi; Salim S Virani; Hani Jneid; Sunil Agarwal; Patricia P Chang; Laura Loehr; Sukhdeep Singh Basra; Wayne Rosamond; Christie M Ballantyne; Anita Deswal
Journal:  Int J Cardiol       Date:  2017-01-31       Impact factor: 4.164

4.  Acarbose treatment enhances mid-regional pro-atrial natriuretic peptide concentrations in non-diabetic individuals: further evidence for a common cardiometabolic pathway?

Authors:  N Rudovich; O Pivovarova; A Traberth; A Sparwasser; M O Weickert; W Bernigau; A L Birkenfeld; A M Arafat; A Bergmann; A F H Pfeiffer
Journal:  Diabetologia       Date:  2012-09-20       Impact factor: 10.122

Review 5.  Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-organ Communication.

Authors:  Gerard Karsenty; Eric N Olson
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

Review 6.  Cardiometabolic aspects of the polycystic ovary syndrome.

Authors:  Harpal S Randeva; Bee K Tan; Martin O Weickert; Konstantinos Lois; John E Nestler; Naveed Sattar; Hendrik Lehnert
Journal:  Endocr Rev       Date:  2012-07-24       Impact factor: 19.871

7.  Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.

Authors:  Nadezhda Glezeva; Patrick Collier; Victor Voon; Mark Ledwidge; Kenneth McDonald; Chris Watson; John Baugh
Journal:  J Cardiovasc Transl Res       Date:  2013-04-27       Impact factor: 4.132

8.  Acute Metabolic Influences on the Natriuretic Peptide System in Humans.

Authors:  Pankaj Arora; Connie Wu; Tariq Hamid; Garima Arora; Obiajulu Agha; Kaitlin Allen; Robert E T Tainsh; Dongjian Hu; Romy A Ryan; Ibrahim J Domian; Emmanuel S Buys; Donald B Bloch; Sumanth D Prabhu; Kenneth D Bloch; Christopher Newton-Cheh; Thomas J Wang
Journal:  J Am Coll Cardiol       Date:  2016-02-23       Impact factor: 24.094

9.  Atrial natriuretic peptide down-regulates LPS/ATP-mediated IL-1β release by inhibiting NF-kB, NLRP3 inflammasome and caspase-1 activation in THP-1 cells.

Authors:  Letizia Mezzasoma; Cinzia Antognelli; Vincenzo Nicola Talesa
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

10.  Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile.

Authors:  Ian J Neeland; Benjamin R Winders; Colby R Ayers; Sandeep R Das; Alice Y Chang; Jarett D Berry; Amit Khera; Darren K McGuire; Gloria L Vega; James A de Lemos; Aslan T Turer
Journal:  J Am Coll Cardiol       Date:  2013-04-16       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.